外傷後ストレス障害(PTSD)の治療のための個別化反復経頭蓋磁気刺激法(PrTMS)
心的外傷後ストレス障害(PTSD)治療のための個別化反復経頭蓋磁気刺激法(PrTMS)
This study is testing a personalized form of brain stimulation called PrTMS as a treatment for post-traumatic stress disorder (PTSD) in military service members and veterans. Unlike standard approaches, this treatment uses a simple brainwave test (EEG) to tailor the therapy to each individual. Participants will be randomly assigned to receive either active treatment or a comparison (sham) treatment over 6 weeks. Researchers will track changes in PTSD symptoms, mood, sleep, and overall well-being, including using wearable devices to measure things like sleep and heart rate. The goal is to see whether this personalized approach can provide greater and longer-lasting relief for individuals living with PTSD.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This study is a randomized, double-blind, sham-controlled trial evaluating a personalized approach to repetitive transcranial magnetic stimulation (PrTMS) for the treatment of post-traumatic stress disorder (PTSD) in military service members and veterans. PrTMS integrates spectral electroencephalography (sEEG) with neurocognitive assessments to individualize stimulation parameters, including frequency and intensity, and to allow for dynamic adjustment over the course of treatment based on each participant's evolving neurophysiological profile. Participants will undergo a 6-week treatment protocol (5 sessions per week), followed by longitudinal assessments over 6 months to evaluate durability of response. Multimodal outcomes will include clinician-administered and self-report measures of PTSD, mood, anxiety, and sleep, as well as physiologic and behavioral data collected via wearable devices. This study is designed to determine whether EEG-guided, precision neuromodulation improves clinical outcomes compared to standard, non-personalized stimulation approaches and to inform the development of individualized treatment strategies in PTSD.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Joseph Bonvie, PsyD
- 電話番号:8572053407
- メール:jbonvie@mgh.harvard.edu
研究連絡先のバックアップ
- 名前:Alan Berkeley, MBA
- 電話番号:8572839928
- メール:aberkeley@mgh.harvard.edu
研究場所
-
-
Massachusetts
-
Charlestown、Massachusetts、アメリカ、02129
- Home Base
-
コンタクト:
- Alan Berkeley, MBA
- 電話番号:8572839928
- メール:aberkeley@mgh.harvard.edu
-
主任研究者:
- Sofia E Matta, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Reserve or former member of the military (veteran status)
- Age 18 years or older
- Primary diagnosis of post-traumatic stress disorder (PTSD) confirmed by the - Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
- Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) score ≥ 33, indicating clinically significant PTSD symptoms
- Proficient in English (spoken and written) to ensure understanding of study procedures and informed consent
Exclusion Criteria:
- History of open-skull traumatic brain injury
- Clinically significant seizure disorder or history of manic episodes
- Neurological conditions associated with increased risk (e.g., increased intracranial pressure, brain lesions, stroke, cerebral aneurysm)
- Electroencephalogram (EEG) abnormalities suggesting elevated seizure risk
- Repetitive transcranial magnetic stimulation (rTMS) within 3 months prior to screening
- Current use of antipsychotic or anticonvulsant medications
- Presence of intracranial implants or non-removable metal in or near the head (excluding the mouth)
- Clinically significant or unstable medical conditions, including active suicidal ideation
- Uncontrolled medical illness (e.g., thyroid, hepatic, cardiac, pulmonary, or renal disease)
- Initiation of PTSD-specific treatment within the past 4 weeks (participants on a stable regimen may be eligible)
- Pregnancy (for women of childbearing potential)
- Any condition that, in the opinion of the investigator, may interfere with study participation or completion
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Active PrTMS (EEG-Guided rTMS)
Participants receive personalized, EEG-guided repetitive transcranial magnetic stimulation (PrTMS) administered 5 days per week for 6 weeks, with stimulation parameters individualized and adjusted over time based on serial sEEG and neurocognitive assessments. |
Personalized repetitive transcranial magnetic stimulation (PrTMS) is delivered using the Neurocare Apollo TMS Therapy System for 30 minutes per session, 5 days per week, over 6 weeks. Stimulation parameters (frequency 8-13 Hz and intensity typically 50-60% of motor threshold) are individualized based on baseline and serial spectral EEG (sEEG) assessments, with adjustments made throughout treatment to optimize response. |
|
偽コンパレータ:Sham PrTMS
Participants receive sham repetitive transcranial magnetic stimulation (rTMS) administered 5 days per week for 6 weeks using a sham coil that mimics the sound and sensation of active treatment without delivering a therapeutic magnetic field. |
Sham stimulation will be delivered using the same Neurocare Apollo TMS Therapy System as the active intervention, with identical treatment schedule (5 days per week for 6 weeks; 30 minutes per session). A sham coil identical in appearance to the active coil will be used, which does not generate a therapeutic magnetic field. To mimic the sensory experience of active treatment, the sham procedure will produce similar auditory clicking and will include a surface electrical stimulation (TENS) applied to the forehead to replicate scalp sensations and mild muscle contraction. This approach is designed to maintain blinding while delivering no active neuromodulatory effect. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
時間枠:At baseline and the end of treatment at Week 6.
|
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a structured interview and gold standard for diagnosing and assessing PTSD in clinical and research settings. It assesses current or lifetime PTSD based on DSM-5 criteria and measures symptom severity across the 20 PTSD symptoms, including the dissociative subtype, in relation to a single index traumatic event. Total severity scores range from 0 to 80, with higher scores indicating worse PTSD symptom severity. |
At baseline and the end of treatment at Week 6.
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5)
時間枠:At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
The Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses PTSD symptom presence and severity across DSM-5 symptom clusters, including re-experiencing, avoidance, negative alterations in cognition and mood, and arousal. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. |
At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
|
Generalized Anxiety Disorder-7 (GAD-7)
時間枠:At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report scale used to assess the severity of generalized anxiety symptoms and to screen for anxiety over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. |
At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
|
Patient Health Questionnaire-9 (PHQ-9)
時間枠:At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure used to screen, diagnose, monitor, and assess the severity of depression. Total scores range from 0 to 27, with higher scores indicating greater depression severity. |
At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
|
Tinnitus Functional Index (TFI)
時間枠:At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
The Tinnitus Functional Index (TFI) is a 25-item self-report questionnaire designed to measure the severity, negative impact, and treatment-related changes of tinnitus on a person's daily life over the past week. Total scores range from 0 to 100, with higher scores indicating greater tinnitus severity and functional impact. |
At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
|
TMS Tolerability Worksheet (TTW)
時間枠:At baseline and weekly during Weeks 1-6.
|
The TMS Tolerability Worksheet (TTW) is a clinician-administered tool used to document session-related side effects and adverse events associated with transcranial magnetic stimulation (TMS), including symptoms such as headache, neck pain, discomfort at the stimulation site, and hearing changes, with severity categorized as none, mild, moderate, or severe. |
At baseline and weekly during Weeks 1-6.
|
|
Pittsburgh Sleep Quality Index Addendum (PSQI-A)
時間枠:At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
The Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) is a self-report measure that assesses disruptive nocturnal behaviors associated with PTSD, including nightmares, panic, hot flashes, and acting out dreams. Total scores range from 0 to 21, with higher scores indicating greater severity of disruptive nocturnal behaviors. |
At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
|
|
Total Sleep Time (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Total sleep time, measured in hours per night using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Sleep Efficiency (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Sleep efficiency, expressed as a percentage (0-100%) representing the ratio of time spent asleep relative to the total time in bed, using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Sleep Latency (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Sleep latency, measured in minutes, defined as the time from the start of the sleep period to sleep onset, as recorded by the Oura Ring wearable device. Typical values range from approximately 0 to 60 minutes. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
REM Sleep Duration (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Duration of rapid eye movement (REM) sleep, measured in minutes using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
REM Sleep Percentage (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
REM sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Light Sleep Duration (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Duration of light sleep, measured in minutes using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Light Sleep Percentage (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Light sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Deep Sleep Duration (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Duration of deep (slow-wave) sleep, measured in minutes using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Deep Sleep Percentage (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Deep (slow-wave) sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Resting Heart Rate (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Resting heart rate, measured in beats per minute (bpm) using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Heart Rate Variability (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Heart rate variability (HRV), measured in milliseconds (ms) using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Body Temperature (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Nightly body temperature deviation from baseline, measured in degrees Fahrenheit (°F) using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Daily Step Count (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Daily step count, measured as the number of steps per day using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Active Energy Expenditure (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Active energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Total Energy Expenditure (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Total energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Sedentary Activity Duration (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Duration of sedentary activity, measured in minutes per day using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Light Activity Duration (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Duration of light physical activity, measured in minutes per day using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Moderate Activity Duration (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Duration of moderate physical activity, measured in minutes per day using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
|
Vigorous Activity Duration (Oura Ring)
時間枠:Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
Duration of vigorous physical activity, measured in minutes per day using the Oura Ring wearable device. |
Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Kaloyan S Tanev, MD、Massachusetts General Hospital
出版物と役立つリンク
一般刊行物
- Makale MT, Nybo C, Blum K, Dennen CA, Elman I, Murphy KT. Pilot Study of Personalized Transcranial Magnetic Stimulation with Spectral Electroencephalogram Analyses for Assessing and Treating Persons with Autism. J Pers Med. 2024 Aug 12;14(8):857. doi: 10.3390/jpm14080857.
- Makale MT, Nybo C, Keifer J, Blum K, Dennen CA, Baron D, Sunder K, Elman I, Makale MR, Thanos PK, Murphy KT. Preliminary Observations of Personalized Repetitive Magnetic Stimulation (PrTMS) Guided by EEG Spectra for Concussion. Brain Sci. 2023 Aug 9;13(8):1179. doi: 10.3390/brainsci13081179.
- Makale MT, Abbasi S, Nybo C, Keifer J, Christman L, Fairchild JK, Yesavage J, Blum K, Gold MS, Baron D, Cadet JL, Elman I, Dennen CA, Murphy KT. Personalized repetitive transcranial magnetic stimulation (prtms(R)) for post-traumatic stress disorder (ptsd) in military combat veterans. Heliyon. 2023 Aug 8;9(8):e18943. doi: 10.1016/j.heliyon.2023.e18943. eCollection 2023 Aug.
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2025P003206
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data (IPD) will not be shared. Only de-identified, aggregate data may be shared with collaborators, including the United States Air Force Research Laboratory (USAFRL), under a data sharing agreement.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。